Study of the Effect of Oral Zinc Supplementation on Superoxide Radical Scavengers

Study of the Effect of Oral Zinc Supplementation on Superoxide Radical Scavengers in Spermatozoa of Patients With Asthenospermia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02217189

Enrollment

120

Registered

2014-08-15

Start date

2011-07-31

Completion date

2012-07-31

Last updated

2017-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthenozoospermia

Keywords

Zinc supplementation., Oxidative stress., Superoxide radical scavengers., Asthenospermia., Oxido-sensitive index.

Brief summary

Although several studies have considered the relationship between infertility and semen super oxide radical scavengers levels, no study on the effects of asthenospermia treatments such as oral zinc supplementation on superoxide radical scavengers activity which are important in fertility of the individual has been reported.

Detailed description

The present study was conducted to study the effect of zinc supplementation on the quantitative and qualitative characteristics of semen along with superoxide radical scavengers activity in the seminal plasma of asthenospermic patients.

Interventions

DIETARY_SUPPLEMENTzinc sulfate

The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

26 Years to 36 Years

Healthy volunteers

Yes

Inclusion criteria

* the presence of asthenozoospermia in the semen sample.

Exclusion criteria

* the absence of endocrinopathy, varicocele, and female factor infertility. Smokers and alcoholic men were excluded from the study because of their recognized high seminal ROS levels and decreased antioxidant levels.

Design outcomes

Primary

Measure	Time frame
Oxido-sensitive index level in spermatozoa and seminal plasma.	up to three months.

Secondary

Measure	Time frame
Xanthine oxidase activity in spermatozoa and seminal plasma.	up to three months.
Catalase like activity in spermatozoa and seminal plasma.	up to three months.
Volume of semen.	up to three months.
Progressive sperm motility percentage.	up to three months
Total normal sperm count.	up to three months.
Superoxide dismutase activity in spermatozoa and seminal plasma.	up to three months.

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026